Tipelukast
- Generic Name
- Tipelukast
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H38O7S
- CAS Number
- 125961-82-2
- Unique Ingredient Identifier
- 08379P260O
- Background
Tipelukast is under investigation for the treatment of IPF and Idiopathic pulmonary fibrosis.
- Associated Conditions
- -
- Associated Therapies
- -
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS
MediciNova announces COMBAT-ALS Phase 2b/3 trial update and interim analysis results of MN-166 (ibudilast) in ALS, showing positive correlations between 6-month and 12-month data, and recommends trial continuation. Over 200 patients enrolled, with trial completion expected in 2026.
MediciNova Announces Update of Phase 2/3 Clinical Trial of
MediciNova announced Dr. Björn Oskarsson's presentation on the Phase 2/3 trial of MN-166 (ibudilast) in ALS at the 2024 NEALS Meeting, discussing study design, objectives, and enrollment updates, along with new NIH funding for an ALS clinical trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath